VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells

Annals of Surgical Oncology

Volumn 19, Issue 8, 2012, Pages 2733-2743

  Doi, Yosuke ^a   Yashiro, Masakazu ^a   Yamada, Nobuya ^a   Amano, Ryosuke ^a   Noda, Satoru ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN ZO1; PROTEIN ZO2; SMALL INTERFERING RNA; SUNITINIB; UVOMORULIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULARLY TARGETED THERAPY; PANCREAS CARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOTTING, WESTERN; CELL MOVEMENT; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDOLES; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; WOUND HEALING;

EID: 84865045103     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2181-6     Document Type: Article

References (43)

1. SP Cleary R Gryfe M Guindi, et al. 2004 Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors J Am Coll Surg 198 722 731 15110805 10.1016/j.jamcollsurg.2004.01.008
2. TA Sohn CJ Yeo JL Cameron, et al. 2000 Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators J Gastrointest Surg 4 567 579 11307091 10.1016/S1091-255X(00)80105-5 1:STN:280:DC%2BD3Mzlt1yqtA%3D%3D
3. LM Ellis DJ Hicklin 2008 VEGF-targeted therapy: mechanisms of anti-tumour activity Nat Rev Cancer. 8 579 591 18596824 10.1038/nrc2403 1:CAS:528:DC%2BD1cXovV2lsro%3D
4. P Buchler HA Reber MW Buchler, et al. 2002 VEGF-RII influences the prognosis of pancreatic cancer Ann Surg. 236 738 749 12454512 10.1097/00000658-200212000-00006 discussion 749
5. N Weidner J Folkman F Pozza, et al. 1992 Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma J Natl Cancer Inst. 84 1875 1887 1281237 10.1093/jnci/84.24.1875 1:STN:280:DyaK3s%2FpsFWhtA%3D%3D
6. Y Ohta Y Tomita M Oda, et al. 1999 Tumor angiogenesis and recurrence in stage I non-small cell lung cancer Ann Thorac Surg. 68 1034 1038 10510003 10.1016/S0003-4975(99)00611-6 1:STN:280:DyaK1MvjslOjsA%3D%3D
7. SI Ishigami S Arii M Furutani, et al. 1998 Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer Br J Cancer 78 1379 1384 9823983 10.1038/bjc.1998.688 1:CAS:528:DyaK1cXns1Wlsb8%3D
8. PJ Paley KA Staskus K Gebhard, et al. 1997 Vascular endothelial growth factor expression in early stage ovarian carcinoma Cancer. 80 98 106 9210714 10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A 1:STN:280:DyaK2szlsVChsg%3D%3D
9. Y Seo H Baba T Fukuda, et al. 2000 High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma Cancer. 88 2239 2245 10820344 10.1002/(SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0. CO;2-V 1:CAS:528:DC%2BD3cXjslSqtbo%3D
10. RF Tang SX Wang L Peng, et al. 2006 Expression of vascular endothelial growth factors A and C in human pancreatic cancer World J Gastroenterol. 12 280 286 16482630
11. Z von Marschall T Cramer M Hocker, et al. 2000 De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop Gastroenterology. 119 1358 1372 10.1053/gast.2000.19578
12. FA Ferrer LJ Miller R Lindquist, et al. 1999 Expression of vascular endothelial growth factor receptors in human prostate cancer Urology. 54 567 572 10475375 10.1016/S0090-4295(99)00156-9 1:STN:280:DyaK1Mvgt1elsg%3D%3D
13. Y Wu AT Hooper Z Zhong, et al. 2006 The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma Int J Cancer 119 1519 1529 16671089 10.1002/ijc.21865 1:CAS:528: DC%2BD28Xos1KhtL8%3D
14. PM Lacal CM Failla E Pagani, et al. 2000 Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor J Invest Dermatol. 115 1000 1007 11121133 10.1046/j.1523-1747.2000.00199.x 1:CAS:528:DC%2BD3MXhtFamug%3D%3D
15. MW Jackson JS Roberts SE Heckford, et al. 2002 A potential autocrine role for vascular endothelial growth factor in prostate cancer Cancer Res. 62 854 859 11830543 1:CAS:528:DC%2BD38Xht1Kru7c%3D
16. DP Lesslie JM Summy NU Parikh, et al. 2006 Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases Br J Cancer 94 1710 1717 16685275 1:CAS:528:DC%2BD28XltVOmtLY%3D
17. M Volm R Koomagi J Mattern 1997 Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer Int J Cancer. 74 64 68 9036871 10.1002/(SICI)1097-0215(19970220)74:1<64::AID-IJC11>3.0. CO;2-I 1:STN:280:DyaK2s7ovVartA%3D%3D
18. K Inoue Y Ozeki T Suganuma, et al. 1997 Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression Cancer. 79 206 213 9010092 10.1002/(SICI)1097-0142(19970115)79:2<206::AID-CNCR2>3.0.CO;2-I 1:STN:280:DyaK2s7mtlamtQ%3D%3D
19. K Maeda YS Chung S Takatsuka, et al. 1995 Tumor angiogenesis as a predictor of recurrence in gastric carcinoma J Clin Oncol. 13 477 481 7531224 1:STN:280:DyaK2M7kslSgtA%3D%3D
20. Yashiro M, Shinto O, Nakamura K, et al. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer. 2009.
21. Kato Y, Yashiro M, Noda S, et al. Establishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinoma. Br J Cancer. 2010;102:898-907.
22. MW Pfaffl 2001 A new mathematical model for relative quantification in real-time RT-PCR Nucleic Acids Res. 29 e45 11328886 10.1093/nar/29.9.e45 1:STN:280:DC%2BD38nis12jtw%3D%3D
23. DB Mendel AD Laird X Xin, et al. 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 327 337 12538485 1:CAS:528:DC%2BD3sXnt1OrtA%3D%3D
24. ER Wood AT Truesdale OB McDonald, et al. 2004 A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res 64 6652 6659 15374980 10.1158/0008-5472.CAN-04-1168 1:CAS:528:DC%2BD2cXnsFOlu7g%3D
25. K Borensztajn J Stiekema S Nijmeijer, et al. 2008 Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation Am J Pathol 172 309 320 18202198 10.2353/ajpath.2008. 070347 1:CAS:528:DC%2BD1cXis1ajurs%3D
26. Shinto O, Yashiro M, Kawajiri H, et al. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer. 2010;102(5):844-51.
27. Doi Y, Masakazu Y, Nobuya Y, Hirakawa K. Significance of phospho-vascular endothelial growth factor receptor-2 expression in pancreatic cancer. Cancer Sci. 2010;101(6):1529-35.
28. H Friess Y Yamanaka M Buchler, et al. 1994 Increased expression of acidic and basic fibroblast growth factors in chronic pancreatitis Am J Pathol. 144 117 128 7507297 1:STN:280:DyaK2c7itFWnug%3D%3D
29. H Friess Y Yamanaka M Buchler, et al. 1993 Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival Gastroenterology. 105 1846 1856 8253361 1:CAS:528: DyaK2cXnsVCksA%3D%3D
30. H Friess Y Yamanaka M Buchler, et al. 1994 Cripto, a member of the epidermal growth factor family, is over-expressed in human pancreatic cancer and chronic pancreatitis Int J Cancer. 56 668 674 8314343 10.1002/ijc.2910560511 1:STN:280:DyaK2c7kvVGluw%3D%3D
31. M Korc B Chandrasekar Y Yamanaka, et al. 1992 Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha J Clin Invest. 90 1352 1360 1401070 10.1172/JCI116001 1:STN:280:DyaK3s%2Fhs1yltA%3D%3D
32. M Kornmann T Ishiwata HG Beger M Korc 1997 Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions Oncogene. 15 1417 1424 9333017 10.1038/sj.onc.1201307 1:CAS:528:DyaK2sXmsFCitrY%3D
33. Y Yamanaka H Friess M Buchler, et al. 1993 Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage Cancer Res. 53 5289 5296 7693336 1:CAS:528: DyaK2cXivVCgsw%3D%3D
34. M Korc 2003 Pathways for aberrant angiogenesis in pancreatic cancer Mol Cancer. 2 8 12556241 10.1186/1476-4598-2-8 1:STN:280:DC%2BD2czltlyhsA%3D%3D
35. P Buchler HA Reber MM Roth, et al. 2007 Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer Neoplasia. 9 119 127 17356708 10.1593/neo.06616 1:CAS:528:DC%2BD2sXktVarurs%3D
36. JP Neoptolemos JA Dunn DD Stocken, et al. 2001 Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial Lancet. 358 1576 1585 11716884 10.1016/S0140-6736(01)06651-X 1:CAS:528:DC%2BD3MXosFKmtro%3D
37. S Ran X Huang A Downes PE Thorpe 2003 Evaluation of novel antimouse VEGFR2 antibodies as potential antiangiogenic or vascular targeting agents for tumor therapy Neoplasia. 5 297 307 14511401 1:CAS:528:DC%2BD3sXovFGqtrg%3D
38. DJ Hicklin LM Ellis 2005 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol. 23 1011 1027 15585754 10.1200/JCO.2005.06.081 1:CAS:528:DC%2BD2MXit1Gnsro%3D
39. SR Wedge DJ Ogilvie 2000 Inhibition of VEGF signal transduction. Identification of ZD4190 Adv Exp Med Biol 476 307 310 10949675 10.1007/978-1-4615-4221-6-25 1:CAS:528:DC%2BD3cXnsFCrtb4%3D
40. JM Wood G Bold E Buchdunger, et al. 2000 PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Res 60 2178 2189 10786682 1:CAS:528:DC%2BD3cXivVaksb0%3D
41. SB Wedam JA Low SX Yang, et al. 2006 Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer J Clin Oncol. 24 769 777 16391297 10.1200/JCO.2005.03.4645 1:CAS:528: DC%2BD28XitVGisbY%3D
42. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 28:3617-22.
43. P Buchler HA Reber A Ullrich, et al. 2003 Pancreatic cancer growth is inhibited by blockade of VEGF-RII Surgery. 134 772 782 14639356 10.1016/S0039-6060(03)00296-4